13.OVERDOSAGE

No overdose or intoxication is known. If an overdose of JINTROPIN has been injected contact should be taken with your physician. 

14.ADVERSE REACTIONS 

Side effects have been noted in approximately 10% (most common local skin reactions) of the patients participating in clinical trials in children with short stature. In clinical trials in adults side effects have been noted in approximately 30 to 40% of the patients, primarily related to symptoms of fluid retention (oedema). These events have an early onset after initiation of therapy, but with a reduction in incidence and prevalence over time and rarely influencing daily activities.JINTROPIN has given rise to the formation of antibodies in very few patients. This has no influence on the treatment result.It has been reported that patients may develop hypothyroidism during treatment with JINTROPIN which should be considered by your physician.If nausea and/or vomiting, severe and recurrent headache especially in combination with visual problems occur take contact with your physician.

15.INCOMPATIBILITIES

Incompatibilities have not been reported for combined use of JINTROPIN with other medicaments or medical solution.

16.SHELF LIFE

The powder for injection is assigned a shelf life of 24 months when stored cold at +2 - +8¡æ. Storage for one month can take place in room temperature.Reconstituted JINTROPIN with preservative may be stored cold at +2 - +8¡æfor 2 weeks protected from light.

17.SPECIAL PRECAUTIONS FOR STORAGE

Frozen powder should not be used. Store cold at +2 - +8¡æ.

18.INSTRUCTIONS FOR USE/HANDLING 

Vials: add solvent to vial with powder for injection. Gently dissolve the drug with a slow,swirling motion. Do not shake vigorously, or the active ingredient might denature. more information on HGH Human Growth Hormone

Jintropin®/ HGH